ABEONA THERAPEUTICS INC.

Abeona Therapeutics is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for rare genetic and inherited diseases. The company's lead program, pz-cel, is an autologous cell-based gene therapy in clinical development for recessive dystrophic epidermolysis bullosa, a severe blistering disorder. Abeona's pipeline also includes several investigational programs targeting ocular conditions: ABO-503 for X-linked retinoschisis, ABO-504 for Stargardt disease, and ABO-505 for autosomal dominant optic atrophy.

The company leverages its AIM vector platform to develop adeno-associated virus (AAV)-based gene therapies across its program portfolio. These programs represent the primary focus of Abeona's research and development activities, with no significant commercial revenues reported from approved products. The company derives funding primarily through capital raises and strategic partnerships rather than product sales.

Abeona operates with approximately 136 full-time employees and maintains its headquarters in Cleveland, Ohio. The company was incorporated in Delaware and is publicly listed on the Nasdaq exchange. Originally founded in 1974 as PlasmaTech Biopharmaceuticals, the company rebranded as Abeona Therapeutics in 2015 to reflect its strategic focus on gene and cell therapy development.